Valeant to buy worldwide rights to Dendreon's Provenge

Jan 29 (Reuters) - Valeant Pharmaceuticals International Inc said it would buy the worldwide rights of Dendreon Corp's Provenge drug and certain other assets through a "stalking horse" deal for $296 million.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.